1. Dipòsit Digital de la Universitat de Barcelona
  2. Recerca
  3. Ciències Clíniques
  4. Articles publicats en revistes (Ciències Clíniques)
Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/110383
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSanmartí Sala, Raimon-
dc.contributor.authorInciarte-Mundo, Jose-
dc.contributor.authorEstrada-Alarcon, Paula-
dc.contributor.authorGarcia-Manrique, Maria-
dc.contributor.authorNarváez García, Francisco Javier-
dc.contributor.authorRodríguez Moreno, Jesús-
dc.contributor.authorGomez-Centeno, Antoni-
dc.contributor.authorPascal i Capdevila, Mariona-
dc.contributor.authorYagüe, Jordi-
dc.date.accessioned2017-05-03T10:54:53Z-
dc.date.available2017-05-03T10:54:53Z-
dc.date.issued2015-08-
dc.identifier.issn0003-4967-
dc.identifier.urihttp://hdl.handle.net/2445/110383-
dc.descriptionArticle en format correspondència-
dc.description.abstractWe read with great interest the paper by Chen et al1 analysing the relationship between therapeutic response to adalimumab and etanercept and serum drug trough levels in 70 patients with rheumatoid arthritis (RA). ...-
dc.format.extent1 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherBMJ Publishing Group-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1136/annrheumdis-2015-207530-
dc.relation.ispartofAnnals of the Rheumatic Diseases, 2015, vol. 74, num. 8, p. e42-
dc.relation.urihttps://doi.org/10.1136/annrheumdis-2015-207530-
dc.rights(c) BMJ Publishing Group, 2015-
dc.sourceArticles publicats en revistes (Ciències Clíniques)-
dc.subject.classificationArtritis reumatoide-
dc.subject.classificationMedicaments-
dc.subject.classificationAdministració de medicaments-
dc.subject.classificationSistema immunològic-
dc.subject.classificationAnticossos monoclonals-
dc.subject.otherRheumatoid arthritis-
dc.subject.otherDrugs-
dc.subject.otherAdministration of drugs-
dc.subject.otherImmune system-
dc.subject.otherMonoclonal antibodies-
dc.titleTowards optimal cut-off trough levels of adalimumab and etanercept for a good therapeutic response in rheumatoid arthritis. Results of the INMUNOREMAR study-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec657895-
dc.date.updated2017-05-03T10:54:54Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
Appears in Collections:Articles publicats en revistes (Ciències Clíniques)

Files in This Item:
File Description SizeFormat 
657895.pdf411.63 kBAdobe PDFView/Open
Show simple item record


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.